Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-12-03 00:00:00 ET · period of report 2024-05-31 · accession 0001787306-24-000166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-12-03 | 2024-05-31+ | ARQT | Watanabe Todd Franklin | See Remarks, Dir | P - Purchase | $3.52 | +6,038 | 838.4K | +0.7% | +$21.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-31 | P | A | 4,000 | $1.69 | 836,392 | D | — | — | (F1) Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-11-30 | P | A | 2,038 | $7.11 | 838,430 | D | — | — | (F1) Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan. |